RecruitingPhase 2NCT06412471
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Enrollment
235 participants
Start Date
Jul 26, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Males and/or females over age 18
- Histologically and/or cytologically documented local advanced or metastatic NSCLC .
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Expected survival >=3 months.
- Signed informed consent form.
Exclusion Criteria5
- Known uncontrolled or symptomatic central nervous system metastatic disease.
- Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
- Inadequate organ or bone marrow function.
- Pregnant or breast-feeding woman.
- Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSSGJ-707
bispecific antibody
DRUGcarboplatin
chemotherapy
DRUGPemetrexed
chemotherapy
DRUGpaclitaxel
chemotherapy
DRUGPD-1/L1
Immune checkpoint inhibitors
DRUGPaclitaxel-albumin
chemotherapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06412471